1. Home
  2. DVAX vs NRP Comparison

DVAX vs NRP Comparison

Compare DVAX & NRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • NRP
  • Stock Information
  • Founded
  • DVAX 1996
  • NRP 2002
  • Country
  • DVAX United States
  • NRP United States
  • Employees
  • DVAX N/A
  • NRP N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • NRP Coal Mining
  • Sector
  • DVAX Health Care
  • NRP Energy
  • Exchange
  • DVAX Nasdaq
  • NRP Nasdaq
  • Market Cap
  • DVAX 1.7B
  • NRP 1.4B
  • IPO Year
  • DVAX 2004
  • NRP N/A
  • Fundamental
  • Price
  • DVAX $12.90
  • NRP $105.23
  • Analyst Decision
  • DVAX Buy
  • NRP
  • Analyst Count
  • DVAX 2
  • NRP 0
  • Target Price
  • DVAX $22.00
  • NRP N/A
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • NRP 31.6K
  • Earning Date
  • DVAX 11-07-2024
  • NRP 11-05-2024
  • Dividend Yield
  • DVAX N/A
  • NRP 2.88%
  • EPS Growth
  • DVAX N/A
  • NRP 4.50
  • EPS
  • DVAX 0.15
  • NRP 12.60
  • Revenue
  • DVAX $260,810,000.00
  • NRP $256,666,000.00
  • Revenue This Year
  • DVAX $21.64
  • NRP N/A
  • Revenue Next Year
  • DVAX $19.81
  • NRP N/A
  • P/E Ratio
  • DVAX $85.33
  • NRP $8.26
  • Revenue Growth
  • DVAX N/A
  • NRP N/A
  • 52 Week Low
  • DVAX $9.74
  • NRP $81.74
  • 52 Week High
  • DVAX $15.01
  • NRP $113.04
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 57.32
  • NRP 47.89
  • Support Level
  • DVAX $12.66
  • NRP $105.05
  • Resistance Level
  • DVAX $13.17
  • NRP $109.32
  • Average True Range (ATR)
  • DVAX 0.29
  • NRP 3.24
  • MACD
  • DVAX -0.04
  • NRP -0.76
  • Stochastic Oscillator
  • DVAX 48.08
  • NRP 30.03

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About NRP Natural Resource Partners LP Limited Partnership

Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. The business activity of the group functions through the United States.

Share on Social Networks: